New Horizons in HSCT-TMA: Expert Perspectives and Pearls for Practice
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
This live educational event is intended for learners to be better able to understand the dynamic data evaluating diagnostic and care strategies for hematopoi…
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
Recent findings support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months.
Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. Research findings …
In the phase 3 ECHO trial, acalabrutinib with bendamustine and rituximab reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Investigators in the Clinical Genetics Branch, led by senior investigator Lisa Mirabello and former research fellow MaĂsa Pinheiro, used deep targeted sequencing to look for…
Join host Dr. Jennifer Shu, medical editor of HealthyChildren.org, and her special guest expert, Dr. Anna Zimmermann, as they discuss the diagnosis, treatmen…
In this issue of Cancer Cell, Son et al. highlight an unexpected role for skin β-papillomaviruses in the protection against skin carcinogenesis. T cell immunity to skin…